^
2ms
Enrollment change • Combination therapy
|
dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • evorpacept (ALX148) • Blenrep (belantamab mafodotin-blmf) • SAR439459 • pegenzileukin (SAR444245)
3ms
Trial completion • Combination therapy • Metastases
|
Libtayo (cemiplimab-rwlc) • SAR439459
5ms
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study. (PubMed, Clin Transl Sci)
SAR'459 monotherapy and combination with cemiplimab appeared relatively safe and tolerable in limited number of patients in dose escalation. However, the study was discontinued due to the unclear efficacy of SAR'459 and bleeding risk, particularly in HCC patients.
Clinical • P1 data • PK/PD data • Clinical Trial,Phase I • Journal • Combination therapy • Metastases
|
TGFB1 (Transforming Growth Factor Beta 1)
|
Libtayo (cemiplimab-rwlc) • SAR439459
6ms
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol (clinicaltrials.gov)
P1/2, N=197, Recruiting, Sanofi | Trial completion date: Dec 2027 --> Mar 2028 | Trial primary completion date: Dec 2027 --> Jun 2027
Trial completion date • Trial primary completion date
|
dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • evorpacept (ALX148) • Blenrep (belantamab mafodotin-blmf) • SAR439459 • pegenzileukin (SAR444245)
9ms
P1 data • PK/PD data • Clinical Trial,Phase I • Journal • Combination therapy • PD(L)-1 Biomarker • Metastases
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • TGFB1 (Transforming Growth Factor Beta 1) • TGFB2 (Transforming Growth Factor Beta 2)
|
Libtayo (cemiplimab-rwlc) • SAR439459
11ms
Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI) (clinicaltrials.gov)
P1, N=24, Recruiting, Sanofi | Phase classification: P1b --> P1 | Trial completion date: Dec 2024 --> Jun 2025
Phase classification • Trial completion date
|
COL1A1 (Collagen Type I Alpha 1 Chain)
|
SAR439459
11ms
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol (clinicaltrials.gov)
P1/2, N=197, Recruiting, Sanofi | N=123 --> 197 | Trial completion date: Nov 2028 --> Dec 2027 | Trial primary completion date: Nov 2028 --> Dec 2027
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
pomalidomide • Sarclisa (isatuximab-irfc) • evorpacept (ALX148) • Blenrep (belantamab mafodotin-blmf) • SAR439459 • pegenzileukin (SAR444245)
over1year
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL (clinicaltrials.gov)
P1b, N=3, Terminated, M.D. Anderson Cancer Center | Trial completion date: Nov 2025 --> Dec 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> Dec 2022; The industry supporter discontinued the study and lead drug, SAR439459, due to toxicity.
Trial completion date • Trial termination • Trial primary completion date • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
Libtayo (cemiplimab-rwlc) • SAR439459
over2years
Clinical • P1 data
|
TGFB1 (Transforming Growth Factor Beta 1)
|
Libtayo (cemiplimab-rwlc) • SAR439459
over2years
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
P1/2, N=280, Recruiting, Hoffmann-La Roche | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • SAR439459 • tobemstomig (RG6139)
almost3years
SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL (clinicaltrials.gov)
P1b, N=3, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 3
Enrollment closed • Enrollment change • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
Libtayo (cemiplimab-rwlc) • SAR439459
3years
Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors (SITC 2021)
Coupled with CD8+ T cell modulation in TME, these findings suggest the identification of early PD biomarkers impacted by SAR439459 which is consistent with the mechanism of action and biological activity of TGFβ blockade therapy. Trial Registration NCT03192345
Clinical • P1 data • PK/PD data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3)
|
Libtayo (cemiplimab-rwlc) • SAR439459
3years
Clinical • Trial completion date
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • SAR439459 • tobemstomig (RG6139)
over3years
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov)
P1/2, N=280, Recruiting, Hoffmann-La Roche | N=100 --> 280 | Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Oct 2021 --> Jul 2024
Clinical • Enrollment change • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • SAR439459 • tobemstomig (RG6139)
over3years
[VIRTUAL] Pan-TGF-β inhibition with PD-1 blockade as a combination treatment strategy to augment anti-tumor immune response in hepatocellular carcinoma (AACR 2021)
In addition, we show that combination therapy was associated with increase in the intra-tumoral levels of proinflammatory cytokines - IFNγ, IL-1β, TNF-α as well as enhanced expression of anti-tumor immune related genes. Based on these data, clinical testing of SAR439459 (TGF-β antibody) and Cemiplimab (anti-PD1) combination has recently been initiated in HCC patients (NCT03192345).
PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta)
|
Libtayo (cemiplimab-rwlc) • SAR439459
over3years
Enrollment open • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
Libtayo (cemiplimab-rwlc) • SAR439459
almost4years
New P1 trial • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
Libtayo (cemiplimab-rwlc) • SAR439459
almost4years
New P1/2 trial • Combination therapy
|
CD38 (CD38 Molecule)
|
pomalidomide • Sarclisa (isatuximab-irfc) • SAR439459
4years
New P1/2 trial
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • amezalpat (TPST-1120) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • SAR439459 • tobemstomig (RG6139)